Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 7/20 | 0.58 |
| ▸ | DHODH | Q02127 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412663 | 0.88 | RAB9A (0.75) | KDM4ERAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL3698974 | 0.88 | RAB9A (0.75) | KDM4ERAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL28321401 | 0.83 | PARP1 (0.58) | KDM4ERAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL3663760 | 0.82 | KDM4E (0.73) | KDM4ERAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL17372933 | 0.81 | RAB9A (0.63) | KDM4ERAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL30335387 | 0.80 | SMN1; SMN2 (0.64) | KDM4ERAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL28978359 | 0.80 | SMN1; SMN2 (0.64) | KDM4ERAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL28322469 | 0.79 | NPC1 (0.62) | RAB9AALDH1A1HPGDKMT2APARP1 | |
| SCHEMBL6258371 | 0.78 | KDM4E (0.55) | KDM4ERAB9AALDH1A1HPGDKMT2A | |
| Terephthalamide SCHEMBL2641517 | 0.78 | CHEK2 (0.76) | KDM4ERAB9AALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436031-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2139474-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009005551-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1742637-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006076009-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | KDM4E 360/4885RAB9A 4067/4885ALDH1A1 3948/4885 |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | KDM4E 360/4885RAB9A 4067/4885ALDH1A1 3948/4885 |
| US-20090131481-A1 | Transcription Factor Modulating Compounds and Methods of Use Thereof | CREBBP, JUN, IRF3 | KDM4E 500/4885RAB9A 3873/4885ALDH1A1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.